VTGN
VistaGen Therapeutics Inc
0.273$
-7.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +267.0% | +275.0% | +203.8% | +24.2% | -58.8% | +1,775.9% | -31.1% | -71.7% | +486.3% | -31.8% | -42.4% | |
| – | +709.2% | +294.9% | +226.3% | +23.8% | -88.4% | +6,488.9% | -31.8% | -75.3% | +589.3% | -32.0% | -42.8% | |
| – | +512.1% | +581.8% | +255.3% | +26.2% | -89.7% | +7,508.9% | -33.9% | -75.6% | +616.2% | -43.7% | -54.1% | |
| – | +512.1% | +581.8% | +255.3% | +26.2% | -89.7% | +7,508.9% | -33.9% | -75.6% | +616.2% | -32.5% | -43.6% | |
| – | – | – | – | – | – | – | +6,663.1% | -70.8% | – | – | – | |
| – | – | – | – | – | – | – | +160.3% | -130.0% | – | – | – | |
| – | -25.2% | +227.1% | -27.6% | +50.8% | +1,111.8% | -5.3% | -88.4% | +568.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -80.9% | -21.9% | +40.9% | +59.0% | +65.8% | +41.7% | -39.1% | -9.3% | +4.0% | +48.9% | -6.5% | |
| – | -89.7% | -23.8% | +6.7% | +92.0% | -1.1% | +51.2% | +37.6% | -20.7% | +12.0% | +146.2% | +1.5% | |
| – | -99.7% | +28.0% | -1.2% | +6.7% | +518.9% | -1.4% | +17.8% | +36.4% | -6.9% | +2.0% | +41.7% | |
| – | -58.4% | -7.3% | +37.9% | -11.8% | +74.1% | -54.4% | +229.1% | -10.4% | -37.4% | -57.8% | +135.1% | |
| – | -91.8% | -55.9% | -25.0% | – | – | – | – | – | – | – | – | |
| – | – | – | +1,023.2% | +2.3% | -181.0% | – | -29.6% | -81.3% | +846.1% | -38.4% | -49.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +34.1% | +326.0% | +84.4% | +105.6% | +53.6% | +96.3% | +129.9% | +5.4% | +178.1% | +59.5% | +23.3% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.